Remove 2023 Remove Chemotherapy Remove Generic Medicine
article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.

article thumbnail

CHMP meeting highlights: January 2024

European Pharmaceutical Review

Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.